These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38566102)

  • 1. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
    Luo WC; Mei SQ; Huang ZJ; Chen ZH; Zhang YC; Yang MY; Liu JQ; Xu JY; Yang XR; Zhong RW; Tang LB; Yin LX; Deng Y; Peng YL; Lu C; Chen BL; Ke DX; Tu HY; Yang JJ; Xu CR; Wu YL; Zhou Q
    J Transl Med; 2024 Apr; 22(1):326. PubMed ID: 38566102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
    Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer.
    Saifon W; Sensorn I; Trachu N; Oranratnachai S; Charoenyingwattana A; Runcharoen C; Monnamo N; Sukkasem W; Inchareon P; Suwatanapongched T; Chansriwong P; Ativitavas T; Panvichian R; Chantratita W; Reungwetwattana T
    BMC Cancer; 2022 Sep; 22(1):963. PubMed ID: 36076157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
    Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
    Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 9. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
    Yamada T; Hirai S; Katayama Y; Yoshimura A; Shiotsu S; Watanabe S; Kikuchi T; Hirose K; Kubota Y; Chihara Y; Harada T; Tanimura K; Takeda T; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Cancer Med; 2019 Apr; 8(4):1521-1529. PubMed ID: 30790471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
    Xin Y; Liu CG; Zang D; Chen J
    Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
    Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y
    Front Immunol; 2022; 13():931718. PubMed ID: 35990690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience.
    Bai M; Wang W; Gao X; Wu L; Jin P; Wu H; Yu J; Meng X
    Front Immunol; 2022; 13():832419. PubMed ID: 35296087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    Kuribayashi T; Ohashi K; Nishii K; Ninomiya K; Tsubata Y; Ishikawa N; Kodani M; Kanaji N; Yamasaki M; Fujitaka K; Kuyama S; Takigawa N; Fujimoto N; Kubota T; Inoue M; Fujiwara K; Harita S; Takata I; Takada K; Okawa S; Kiura K; Hotta K
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):89. PubMed ID: 38347279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the Efficacy of Immunotherapy on the Posterior Lines 
of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer].
    Ma L; Qin N; Zhang X; Wu Y; Li H; Yu M; Liu Z; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):338-344. PubMed ID: 34034457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
    Liu Y; Miao J
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):934-942. PubMed ID: 38163979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.
    Chen D; Li L; Wang M; Hu X; Jiang J; Li W; Yang L; Fan M; Shi Y; Lv F; Liu Y
    Front Immunol; 2023; 14():1086479. PubMed ID: 37795095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
    Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
    BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients 
with Advanced EGFR Positive NSCLC and Its Relationship with the 
Therapeutic Efficacy of EGFR-TKIs].
    Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.